Evidence map›Paper›PMID 41299643›Full record

ArticleBMC medical genomics2025

Transcriptomic profiling of DYT-TOR1A patient-derived iPSC reveals dysregulation in extracellular matrix, lipid metabolism, and Chr22q11.23.

Núria Setó-Salvia, Henry Houlden, Thomas T Warner

Abstract read
In one paragraph

Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Núria Setó-SalviaDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK. n.seto-salvia@ucl.ac.uk.
Henry HouldenDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.
Thomas T WarnerDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDYT-TOR1A is an early-onset generalised movement disorder characterised by involuntary muscle contractions, leading to abnormal postures and repetitive movements. The trinucleotide GAG in-frame deletion (ΔGAG) in the TOR1A gene is the most common Mendelian form of dystonia. The TOR1A gene encodes for TorsinA protein, involved in several molecular functions, including chaperone activity, protein quality control, synaptic vesicle recycling, vesicular trafficking, protein folding, homeostasis of the nuclear envelope integrity, and lipid metabolism. There is increasing evidence that DYT-TOR1A dystonia is a neurodevelopmental disorder, beginning in the period where structural and functional abnormalities manifest early in physiological maturation. Recent publications have highlighted the importance of the extracellular matrix and lipid metabolism in dystonia, processes important to cellular neurodevelopment. In this study we aimed to elucidate the gene expression profiles of mutant DYT-TOR1A patient-derived iPSCs to identify key pathways and differentially expressed proteins involved in the early stages of neurodevelopment.

resultsOf the 39,065 genes analysed, 1,322 were found to be significantly dysregulated (p < 0.05). For the purposes of this study, we focus on the 36 most significantly dysregulated genes (q < 0.05) and discuss their biological relevance. We identified 28 upregulated and 8 downregulated genes in human DYT-TOR1A patient-derived induced pluripotent stem cells (iPSCs). Most of the encoded proteins constitute fundamental components of extracellular matrix and lipid metabolism, suggesting impairments related to the microenvironment for cell growth, and cell differentiation, membrane fluidity, receptor trafficking, as well as neurodevelopment. In addition, we identified changes in the expression of genes coding for nuclear proteins, suggesting dysregulation in transcription factors involved in development, particularly in the forebrain and hippocampus. Interestingly, a high proportion of dysregulated genes are localised on Chromosome 22q11.23.

conclusionsOur study in iPSC-derived from DYT-TOR1A patients shows a transcriptomic profile, which validates previous candidate genes highlighted in other animal models of dystonia. We believe that our results will help elucidate early mechanisms in neurodevelopment of DYT-TOR1A dystonia.

Indexed as

DystoniaExtracellular MatrixGene Expression ProfilingInduced Pluripotent Stem CellsLipid MetabolismMolecular ChaperonesHumansMolecular ChaperonesTOR1A protein, humanChr22q11.23DYT-TOR1A dystoniaExtracellular matrixiPSCsLipid metabolismRNA-seqTranscriptomic profile

Identifiers

PMID41299643
PMCPMC13403586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.